Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04848662 · ClinicalTrials.gov registry record · Phase 1
To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.
A Phase 1 study, sponsored by Bond Avillion 2 Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04848662: Completed Phase 1 study, sponsored by Bond Avillion 2 Development.
NCT04848662 is a Phase 1 study that has completed, run by Bond Avillion 2 Development. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04848662, a Phase 1 study, has completed, sponsored by Bond Avillion 2 Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years.
Interventions
- DRUG BDA MDI (PT027) 160/180 μg
- DRUG Pulmicort Respules 0.5 MG/ML Inhalation Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-05-06 |
| Est. Completion | 2021-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04848662
The ClinicalTrials.gov registry entry for NCT04848662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bond Avillion 2 Development, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BDA MDI (PT027) 160/180 μg is the first listed.
NCT04848662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04848662 about?
NCT04848662 is a clinical study titled "To Compare the Pharmacokinetics of Budesonide Delivered by BDA MDI to Budesonide Delivered by Pulmicort Respules in Children With Asthma Aged 4 to 8 Years.". To compare the pharmacokinetics of budesonide delivered by BDA MDI to budesonide delivered by Pulmicort Respules in children with Asthma aged 4 to 8 years.
What is the current status of trial NCT04848662?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2021-05-06. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT04848662?
The interventions under investigation include: BDA MDI (PT027) 160/180 μg (DRUG), Pulmicort Respules 0.5 MG/ML Inhalation Suspension (DRUG).
Who is sponsoring clinical trial NCT04848662?
This trial is sponsored by Bond Avillion 2 Development, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.